Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer.

PURPOSE To explore the efficacy and safety of irreversible electroporation (IRE) ablation combined with natural killer (NK) cells in the treatment of locally advanced pancreatic cancer (LAPC). METHODS A total of 92 LAPC patients treated in our hospital from January 2016 to January 2017 were enrolled, and there were 46 cases of percutaneous IRE as IRE group, and 46 cases of IRE combined NK cell therapy as IRE-NK group. The clinical information of all the patients was collected, and the short-term efficacy, changes in the serum immunological indicators after treatment, carbohydrate antigen 19-9 (CA19-9) level, and incidence of adverse reactions were compared between the two groups of patients. Besides, the overall survival (OS) and disease-free survival (DFS) of patients were followed up and recorded. RESULTS On 1 month after treatment, all the patients underwent efficacy assessment, which showed the overall response rate of patients in IRE-NK group was significantly superior to that in IRE group. One and 7 days after operation, the level of CA19-9 was obviously raised in the two groups, with a statistically significant difference, and it declined 30 days postoperatively. Seven and 30 days after operation IRE-NK group had a notably lower level of CA19-9 than IRE group. After treatment, all the patients exhibited considerably higher lymphocyte count and notably enhanced lymphocyte function, and all the indicators in IRE-NK group were higher than those in IRE group. Besides, the levels of serum interleukin (IL)-2, TNF-β and IFN-γ in IRE-NK group were remarkably higher than those in IRE group, whereas there were no statistically significant differences in the levels of IL-4, IL-6 and IL-10 between the two groups. All the patients were followed up for 6-29 months, and there were no statistically significant differences in the DFS and OS between IRE group and IRE-NK group. CONCLUSION IRE ablation combined with NK cells has excellent efficacy in treating LAPC, and they can exert a synergistic treatment effect to enhance the immune function of patients and reduce CA19-9 expression, with tolerable adverse reactions.

[1]  N. Zengi̇n,et al.  Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[2]  A. Tentes,et al.  Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[3]  S. Chalikonda,et al.  Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. , 2015, Annals of surgery.

[4]  Rongguo Li,et al.  Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway , 2015, OncoTargets and therapy.

[5]  Hu Chen,et al.  Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer , 2014, BMC Cancer.

[6]  Y. Zeng,et al.  Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[7]  Robert C. G. Martin,et al.  Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. , 2014, Journal of the American College of Surgeons.

[8]  H. Harizi Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology , 2013, Cellular and Molecular Immunology.

[9]  A. Mikelsaar,et al.  Epitope of titin A-band-specific monoclonal antibody Tit1 5 H1.1 is highly conserved in several Fn3 domains of the titin molecule. Centriole staining in human, mouse and zebrafish cells , 2012, Cell Division.

[10]  Kecheng Xu,et al.  Cryosurgery for lung cancer. , 2012, Journal of thoracic disease.

[11]  E. Leen,et al.  Irreversible Electroporation for Focal Ablation at the Porta Hepatis , 2012, CardioVascular and Interventional Radiology.

[12]  Li-Zhi Liu,et al.  Autologous Cytokine-induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma , 2012, Journal of immunotherapy.

[13]  Helen Kavnoudias,et al.  Investigation of the safety of irreversible electroporation in humans. , 2011, Journal of vascular and interventional radiology : JVIR.

[14]  Jens Ricke,et al.  Irreversible Electroporation of Renal Cell Carcinoma: A First-in-Man Phase I Clinical Study , 2011, CardioVascular and Interventional Radiology.

[15]  D. Dupuy,et al.  Irreversible electroporation of the pancreas in swine: a pilot study. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[16]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[17]  Boris Rubinsky,et al.  Tumor Ablation with Irreversible Electroporation , 2007, PloS one.

[18]  Boris Rubinsky,et al.  In vivo results of a new focal tissue ablation technique: irreversible electroporation , 2006, IEEE Transactions on Biomedical Engineering.

[19]  Boris Rubinsky,et al.  Electrical impedance tomography for imaging tissue electroporation , 2004, IEEE Transactions on Biomedical Engineering.

[20]  S. Bagla,et al.  Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report. , 2012, Journal of vascular and interventional radiology : JVIR.

[21]  L. Downs,et al.  A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.

[22]  B. Rubinsky,et al.  Tissue Ablation with Irreversible Electroporation , 2005, Annals of Biomedical Engineering.

[23]  N. Dubrawsky Cancer statistics , 2022 .